#Visual paradigm review software
You may use the Software only on computers that are part of the Academic Institution's internal network domain.Įxcept as otherwise provided herein, you may use the Software only on computers that are located at the Academic Institution's permanent facilities. You may make additional copies of the User Documentation for internal purposes. You may make a copy of the Software solely for use as backup and not to be sold, loaned, leased, gifted, or otherwise transferred or used by any other person. The recipient agrees to use the Software solely for non-commercial classroom teaching and shall not distribute or transfer it to another location or to any other person without prior written permission from Visual Paradigm.
If you do not agree to the terms of this Agreement, promptly return the Software to Visual Paradigm. By accepting, receiving, and using this Software, you are agreeing to be bound by the terms of this Agreement. This is a legal agreement between you, the recipient, and Visual Paradigm.
#Visual paradigm review license
The license expires as soon as you are no longer a member of this institution. I think it's going to be a whole new genre therapeutic way to treat our patients and help bring back this longevity and health to the eye.This license applies to you, the recipient, only if you are a member of a non-commercial and academic institution, e.g., a university. But, it's in the bench and it's very exciting to see that this whole field of laser scleral microporation is a tissue that's not been addressed. We're also doing some interesting things with ocular drug delivery laser-assisted ocular drug delivery, which is not coming soon. Being that presbyopia isn't the only indication of use, we're developing a glaucoma IOP-reducing microporation pattern. We have a lot of surprises coming in microporation therapeutics. They can just focus like they naturally do. They don't have to walk around with glasses or drops or anything in their pockets. We're making our our patients visual age younger and younger to match their lifestyle and their health-related quality of life is improved because they don't feel old. Immediately, they get about 18 years of rejuvenation. So, we were able to rejuvenate our patient population, almost 15 years over 2 years sustained. So we had a unique way and a unique proprietary formula to convert distance-corrected, near-visual acuity into what is your visual age. Some people were in readers early, 40 42. You have a biological age, you have a chronological age, and you have a visual age. Dr Jim Katz and Dr Elizabeth Yeu are presenting at this congress, The Visual Age. We actually created a novel way to look at this disability called presbyopia. We're getting ready to roll out all the nuggets out of those studies. It's been a great experience to close up that study. Patients are happy, the satisfaction is great. We presented, today with Dr Bobby Ang, 100 Eyes of 50 patients, data looking very good, sustaining results over 2 years. The VisioLite currently, which was developed in Liechtenstein, is in Boston, our new headquarters, getting ready to go to the FDA next year. But, it's been a really long journey to get here. It's so simple that it seems hard to wrap your brain around. Basically, it restores the natural dynamic range of focus function in the eye that moves the lens. That happens with age, cramping those muscles, not allowing them to move. It's a true biomechanical treatment that's attacking this ocular rigidity from cross-linking in the sclera. There is no therapy that does restore the dynamic range of focus, it doesn't touch the cornea, it doesn't touch the lens.
Our patients read their phones right away. It's touchless, it's painless, and it takes 10 minutes. It is a scleral microporation with an erbium YAG.
That lifecycle being from onset all the way through. It is one of the first devices, which is a laser therapy, basically treats presbyopia during the entire lifecycle. We are very ecstatic about bringing the new microporation therapeutic technology into ophthalmology. So, Ace Vision Group has 9 scientific papers and posters combined for the International Society of Presbyopia Meeting and also the ESCRS meeting.
This transcript has been lightly edited for clarity. AnnMarie Hipsley, DPT, PhD, Founder and CEO of Ace Vision Group, met with Ophthalmology Times Europe at the 2023 European Society of Cataract and Refractive Surgeons to discuss Ace Vision Group's microporation therapeutic technology, used to treat presbyopia.
0 kommentar(er)
